Newsroom

Sorted by: Latest
-

Resumen: Imprimiendo el futuro de la oncología: CTIBIOTECH invierte 3 millones de euros y obtiene 1,25 millones de euros de France 2030 para transformar la atención oncológica personalizada

LYON, Francia--(BUSINESS WIRE)--CTIBIOTECH anuncia el proyecto CTIONCOTEST™, una iniciativa destinada a transformar la investigación oncológica a través de microtumores en 3D realizados con tecnologías de bioimpresión, con el respaldo de France 2030 y Bpifrance. CTIBIOTECH™, una innovadora compañía francesa de investigación, desarrollo y fabricación por contrato (CRDMO), con sede en Meyzieu (Lyon), anuncia el lanzamiento del proyecto CTIONCOTEST™, una iniciativa pionera de 3 millones de euros o...
-

Riassunto: Stampare il futuro dell'oncologia: CTIBIOTECH investe 3 milioni di euro e si assicura 1,25 milioni di euro da France 2030 per rivoluzionare le cure oncologiche personalizzate

LIONE, Francia--(BUSINESS WIRE)--CTIBIOTECH annuncia il progetto CTIONCOTEST ™ per rivoluzionare la ricerca sul cancro con microtumori biostampati in 3D, con il sostegno di France 2030 e Bpifrance CTIBIOTECH™, un'organizzazione a contratto di ricerca, sviluppo e produzione (CRDMO) innovativa con sede a Meyzieu-Lyon, è fiera di annunciare il lancio del progetto CTIONCOTEST ™, un'iniziativa rivoluzionaria da 3 milioni di euro finalizzata a trasformare la ricerca oncologica preclinica. Per acceler...
-

Samenvatting: De toekomst van de oncologie in 3D-bioprint: CTIBIOTECH investeert 3 miljoen euro en ontvangt 1,25 miljoen euro van France 2030 voor een radicale ommekeer in gepersonaliseerde kankerzorg

LYON, Frankrijk--(BUSINESS WIRE)--CTIBIOTECH kondigt het CTIONCOTEST™-project aan, bedoeld om baanbrekend werk te verrichten in het kankeronderzoek met behulp van het 3-D-bioprinten van microtumoren, ondersteund door France 2030 en Bpifrance CTIBIOTECH™, een innovatief Frans bedrijf voor contractonderzoek, -ontwikkeling en -productie (CRDMO), gevestigd in Meyzieu-Lyon, kondigt met trots de lancering aan van het CTIONCOTEST ™-project, een grensverleggend initiatief van 3 miljoen euro met als doe...
-

Die Zukunft der Onkologie drucken: CTIBIOTECH investiert 3 Mio. € und erhält 1,25 Mio. € von „France 2030“, um die personalisierte Krebsbehandlung zu revolutionieren

LYON, Frankreich--(BUSINESS WIRE)--CTIBIOTECH kündigt das Projekt CTIONCOTEST ™ an, das die Krebsforschung mit 3D-biogedruckten Mikrotumoren revolutionieren soll, unterstützt von France 2030 und Bpifrance CTIBIOTECH™, ein innovatives französisches Auftragsforschungs-, Entwicklungs- und Produktionsunternehmen (CRDMO) mit Sitz in Meyzieu-Lyon, gibt stolz den Start des CTIONCOTEST™-Projekts bekannt, einer bahnbrechenden 3-Millionen-Euro-Initiative, die darauf abzielt, die präklinische Krebsforschu...
-

L'avenir de l'oncologie par l'impression : CTIBIOTECH investit 3 millions d'euros et obtient 1,25 million d'euros du programme France 2030 pour révolutionner les soins personnalisés en cancérologie

LYON, France--(BUSINESS WIRE)--CTIBIOTECH présente le projet CTIONCOTEST ™ visant à révolutionner la recherche sur le cancer grâce à des microtumeurs bio-imprimées en 3D, avec le soutien de France 2030 et de Bpifrance CTIBIOTECH™, une organisation française innovante de recherche, de développement et de fabrication sous contrat (CRDMO) située à Lyon-Meyzieu, annonce fièrement le lancement du projet CTIONCOTEST ™, une initiative révolutionnaire de 3 millions d'euros visant à transformer la reche...
-

Peraton Achieves CMMC Final Level 2, Reinforcing Commitment to Secure, Uninterrupted Mission Support

RESTON, Va.--(BUSINESS WIRE)--Peraton announced today that it has achieved Final Level 2 certification under the Cybersecurity Maturity Model Certification (CMMC) program following a successful assessment by a CMMC Certified Third-Party Assessment Organization. This milestone underscores the company's commitment to cybersecurity excellence for its customers. The CMMC framework, developed by the Department of War (DoW), establishes rigorous cybersecurity standards for sensitive information acros...
-

BancPlus Corporation Announces Quarterly Cash Dividend

RIDGELAND, Miss.--(BUSINESS WIRE)--BancPlus Corporation, the holding company for BankPlus, today announced that on April 28, 2026, its Board of Directors declared a quarterly cash dividend of $0.53 per share of its common stock. The cash dividend is equivalent to an annualized dividend of $2.12 per share. The cash dividend will be paid on June 15, 2026, to shareholders of record as of the close of business on May 15, 2026. About BancPlus Corporation BancPlus Corporation is the holding company o...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Capital Strength UCITS ETF 28.04.2026 FTCS. IE00BL0L0D23 325,002.00 USD 10,512,493.12 32.346  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Value Line Dividend Index UCITS ETF 28.04.2026 FVD. IE00BKVKW020 250,002.00 USD 7,291,733.07 29.167  ...
-

Bryant & Stratton College Opens New Richmond - Chesterfield Campus to Expand Healthcare Workforce Pipeline

NORTH CHESTERFIELD, Va.--(BUSINESS WIRE)--Bryant & Stratton College officially opened its newly relocated Richmond - Chesterfield Campus today with a ceremonial ribbon-cutting event. The new campus is designed to expand access to career-focused education and help address the growing demand for healthcare workers across Central Virginia. The new 53,000-square-foot facility, located at 101 Gateway Centre Parkway, Suite 210, will accommodate hundreds of future healthcare professionals and is e...